|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 7,906,542 (Rifaximin Polymorphs α/β/γ with Plasma Exposure Limits)
US 7,906,542 claims rifaximin polymorphic forms (Form α, Form β, Form γ) defined by X-ray powder diffraction (XRPD) peak sets, moisture ranges, and performance in vivo defined by plasma concentration limits plus PK endpoints (tmax, AUC0-24h). The practical claim scope is narrow in the “what” (specific polymorph identities and their XRPD/moisture) and narrow in the “how it behaves in humans” (upper-bound plasma exposure and specific tmax/AUC0-24h targets).
Core infringement test (at a high level): an accused product must (i) contain rifaximin that is in the claimed polymorph form (as established by XRPD peak positions, and optionally moisture and intrinsic dissolution), and (ii) deliver human plasma exposure that meets the claimed upper bounds and/or PK parameters.
What does US 7,906,542 claim about rifaximin polymorphic Form α, and how broad is it?
Claim 1 anchors Form α to a specific XRPD fingerprint and a plasma exposure ceiling. Dependent claims add moisture and formulation/instrumentation variants.
Claim 1 key limitations
- Composition: pharmaceutical composition comprising rifaximin Form α plus pharmaceutically acceptable excipient/carrier.
- XRPD peaks for Form α: about 7.4°; 19.7°; 21.0°; 22.1° (2θ).
- Human plasma exposure ceiling: observed plasma concentration of rifaximin ≤ about 2.6 ng/mL after administration.
Interpretation for scope
- The XRPD peak set is claim-defining. If an accused formulation uses a different polymorph, a different form, or a mixture that fails the claimed peak pattern, it does not meet the polymorph identity limitation.
- The plasma ceiling is also claim-defining. Even if XRPD matches, PK must be at or below the stated exposure.
Dependent claims tied to Form α
- Claim 2: Form α water content ~2% to ~3%.
- Claim 3: excipient category is limited to listed excipient types (diluting, binding, lubricating, disintegrating, coloring, flavoring, sweetening).
- Claim 4: broad dosage form and packaging concepts:
- coated/uncoated tablets
- hard/soft gelatin capsules
- sugar-coated pills
- lozenges
- wafer sheets
- pellets and powders in sealed packet
- Claim 5: tmax ~9.5 hours for Form α.
- Claim 6: AUC0-24h ~13 ng·h/mL for Form α.
- Claims 7-8 are duplicates of Claims 5-6 as tied to Claim 2.
Scope takeaways for Form α
- Broad: dosage form and excipient types are wide (Claim 4, Claim 3).
- Narrow: polymorph identity (XRPD), moisture (Claim 2), and exposure targets (≤2.6 ng/mL; plus tmax/AUC) constrain coverage.
What patents (and likely related families) typically cover rifaximin polymorphs, and how does 7,906,542 fit?
US 7,906,542 is structurally a polymorph-performance patent: it couples (a) solid-state identity (XRPD peak sets; moisture; intrinsic dissolution) with (b) human PK outcomes (plasma concentration ceilings; tmax; AUC). That pattern is common in rifaximin crystallinity/polymorph families where the manufacturer argues that polymorph selection alters bioavailability and therefore the “real-world” performance of an oral solid.
Claim architecture in 7,906,542
- Three independent claim blocks: Form α (Claim 1), Form β (Claim 9), Form γ (Claim 18).
- Each block is then tightened by dependent properties:
- moisture ranges (Claims 2, 10, 20)
- intrinsic dissolution (Claims 17, 19)
- excipient/formulation categories (Claims 3, 11, 21 and 4, 12, 22)
- specific PK endpoints (Claims 5-8, 13-16, 23-25)
Practical positioning
- If there are other rifaximin polymorph patents, they tend to claim:
- methods for preparing a polymorph,
- polymorphs defined by different analytical descriptors (DSC, IR, SSR),
- or formulations without human PK ceilings.
- US 7,906,542 is more defensible against “different formulation” workarounds because it includes human plasma exposure thresholds. The downside is that it can be harder to prove without clean PK evidence and polymorph characterization.
What does US 7,906,542 claim about rifaximin polymorphic Form β, and what are the defining exposure limits?
Claim 9 anchors Form β to a different XRPD signature and a lower plasma ceiling.
Claim 9 key limitations
- Composition: pharmaceutical composition comprising rifaximin Form β plus pharmaceutically acceptable excipient/carrier.
- XRPD peaks for Form β: about 5.4°; 9.0°; 20.9° (2θ).
- Human plasma exposure ceiling: observed plasma concentration of rifaximin ≤ about 1.1 ng/mL.
Dependent claims tied to Form β
- Claim 10: Form β water content > about 4.5%.
- Claim 11: excipient limited to the enumerated excipient categories.
- Claim 12: same broad dosage form/packaging universe as Claim 4.
- Claim 13: tmax ~4 hours.
- Claim 14: AUC0-24h ~11 ng·h/mL.
- Claims 15-16 repeat Claims 13-14 tied to Claim 10.
- Claim 17: intrinsic dissolution rate ~0.014 mg/min/cm².
Scope takeaways for Form β
- Highly constrained by both XRPD signature and PK limits.
- Moisture limitation (>4.5%) and dissolution rate provide extra handles to distinguish Form β from other forms or mixtures.
What does US 7,906,542 claim about rifaximin polymorphic Form γ, and what are the defining PK and dissolution limits?
Claim 18 anchors Form γ to another XRPD signature plus a very high plasma exposure ceiling.
Claim 18 key limitations
- Composition: pharmaceutical composition comprising rifaximin Form γ plus excipient/carrier.
- XRPD peaks for Form γ: about 5.0°; 7.1°; 8.4° (2θ).
- Human plasma exposure ceiling: observed plasma concentration of rifaximin ≤ about 668 ng/mL.
Dependent claims tied to Form γ
- Claim 19: intrinsic dissolution rate ~0.14 mg/min/cm².
- Claim 20: water content ~1% to ~2%.
- Claim 21: excipient limited to enumerated excipient categories.
- Claim 22: dosage form/packaging broad list (tablets, capsules, pills, lozenges, wafer sheets, pellets and powders in sealed packet).
- Claim 23: tmax ~2.3 hours.
- Claim 24: repeats Claim 23 with Claim 20 dependency.
- Claim 25: AUC0-24h ~4000 ng·h/mL.
Scope takeaways for Form γ
- Form γ is the least “tight” on the plasma ceiling (≤668 ng/mL is far higher than Form α and β ceilings), but it is tightly defined by XRPD peaks and dissolution/moisture in dependent claims.
- If an accused product delivers plasma levels below the claimed ceiling, it can still be outside the claim if the polymorph identity fails XRPD and the dissolution/moisture restrictions (where asserted) are not met.
How do the claim values map into a practical “infringement scoreboard” for polymorph identification and human PK?
| Claimed element |
Form α (Claim 1) |
Form β (Claim 9) |
Form γ (Claim 18) |
| XRPD defining peaks (2θ) |
~7.4, 19.7, 21.0, 22.1 |
~5.4, 9.0, 20.9 |
~5.0, 7.1, 8.4 |
| Plasma concentration cap |
≤2.6 ng/mL |
≤1.1 ng/mL |
≤668 ng/mL |
| Moisture constraint (dependent) |
~2% to ~3% (Claim 2) |
>~4.5% (Claim 10) |
~1% to ~2% (Claim 20) |
| tmax (dependent) |
~9.5 h (Claim 5) |
~4 h (Claim 13) |
~2.3 h (Claim 23) |
| AUC0-24h (dependent) |
~13 ng·h/mL (Claim 6) |
~11 ng·h/mL (Claim 14) |
~4000 ng·h/mL (Claim 25) |
| Intrinsic dissolution (dependent) |
not in independent; none specified for α |
~0.014 mg/min/cm² (Claim 17) |
~0.14 mg/min/cm² (Claim 19) |
Business significance
- The claim set is not a generic “rifaximin composition” umbrella; it is a solid-state and performance-specific umbrella.
- Licensing or generic design-around strategies often focus on:
- switching polymorph form,
- producing a mixture that shifts XRPD peak profile,
- controlling moisture to avoid the claimed ranges,
- and targeting different dissolution behavior.
- However, because there are explicit in-vivo PK endpoints, an infringer cannot rely solely on lab characterization if human exposure still matches the claimed endpoints.
What claim scope exists for excipients and dosage forms, and does that broaden infringement?
Across Claims 3, 11, 21 and Claims 4, 12, 22, the patent treats:
- excipient categories as broad and enumerated,
- dosage forms as broad within oral solids and sealed packets.
What is broad
- Excipients are defined by functional categories (diluting, binding, lubricating, disintegrating, coloring, flavoring, sweetening).
- Dosage form list includes tablets, capsules, pills, lozenges, wafer sheets, pellets, powders in sealed packet.
What is not broad
- The active ingredient polymorph identity and its characterization (XRPD peak pattern) are not broad.
- The claimed in vivo exposure caps and PK targets are not broad.
Net effect: dosage form and excipients do not materially expand coverage beyond the polymorph-and-PK requirement. A product that uses the claimed polymorph but changes formulation to alter dissolution and PK still has an infringement risk profile driven by whether PK caps/parameters are met.
When does US 7,906,542 lose exclusivity, and what launch timing does that imply?
No filing date, priority date, maintenance status, term adjustment, or patent term extension information is provided in the prompt. Without that data, a correct exclusivity/timing analysis cannot be produced.
What Orange Book status exists for US 7,906,542 and which products would be exposed?
No Orange Book listing identifiers, NDA/BLA numbers, or Orange Book patent codes are provided in the prompt. Without those data, a compliant mapping to specific FDA-listed rifaximin products cannot be produced.
What generic entry risks exist for polymorph-specific rifaximin patents like 7,906,542?
Given the claim set, the key generic entry risks are technical and evidentiary:
- Polymorph risk: If the generic uses a manufacturing process that yields Form α, β, or γ matching the claimed XRPD peaks, the product can fall inside the “what” limitation even if the generic uses different excipients or tablet/capsule hardware.
- Moisture/dissolution risk: Dependent claims add water content and intrinsic dissolution rate. Moisture control in manufacturing and storage (humidity excursions) can create risk if the product shifts into the claimed water/dissolution window.
- PK risk: Even if the generic matches XRPD, the patent claims human plasma caps and specific tmax/AUC. If formulation or crystallinity affects absorption and exposure such that PK meets the claimed profiles, infringement exposure increases.
- Proof risk for litigation: The patent’s strength depends on the availability of:
- reliable XRPD methods for the polymorph,
- validated moisture and dissolution testing,
- and human PK data comparing claimed endpoints.
What patent litigation angles are implicated by the structure of these claims?
Even without case docket information, the claim structure implies typical litigation focal points:
- Polymorph infringement (XRPD matching): Disputes typically center on whether the accused material exhibits the claimed XRPD peak positions within the “about” tolerances.
- Moisture and dissolution: Dependent claims can be litigated using moisture testing and intrinsic dissolution methods. Differences in methodology can become dispositive.
- PK thresholds: The “observed plasma concentration” ceiling and the tmax/AUC0-24h limits can drive the need for clinical bridging studies or reliance on published PK for the product.
- Device for design-around: Changing polymorph form or controlling moisture may avoid XRPD and dependent conditions, but PK limits can still create exposure.
Key Takeaways
- US 7,906,542 covers rifaximin compositions defined by polymorph-specific XRPD peak sets plus human plasma exposure limitations.
- The patent’s real boundary is not excipients or dosage forms. It is solid-state identity (polymorph) and in vivo performance (plasma concentration, tmax, AUC0-24h; plus water content and intrinsic dissolution in dependent claims).
- Form α: XRPD ~7.4/19.7/21.0/22.1; plasma ≤2.6 ng/mL; tmax ~9.5 h; AUC0-24h ~13.
- Form β: XRPD ~5.4/9.0/20.9; plasma ≤1.1 ng/mL; tmax ~4 h; AUC0-24h ~11; intrinsic dissolution ~0.014 mg/min/cm².
- Form γ: XRPD ~5.0/7.1/8.4; plasma ≤668 ng/mL; tmax ~2.3 h; AUC0-24h ~4000; intrinsic dissolution ~0.14 mg/min/cm².
FAQs
1) If an accused rifaximin product matches the XRPD peaks, does it automatically infringe US 7,906,542?
No. Claims also require meeting the claimed human plasma exposure ceiling and, for dependent claims, tmax and AUC0-24h and other dependent performance limits.
2) How do “about” values affect polymorph and PK claim scope in US 7,906,542?
They create tolerance around the stated peak positions and PK parameters. In practice, “about” expands dispute over acceptable analytical and statistical ranges.
3) Which dependent claims are most design-around sensitive: moisture or intrinsic dissolution?
Moisture and intrinsic dissolution are both sensitive. Moisture can be adjusted through drying and packaging controls; dissolution depends on crystal form, particle properties, and processing.
4) Could changing dosage form (tablet vs capsule) avoid infringement?
Only if the change prevents meeting the polymorph identity and/or the claimed PK endpoints. Claim 4/12/22 are broad on dosage forms, so dosage form alone is unlikely to be sufficient.
5) What is the highest litigation leverage point in this patent?
The coupling of XRPD polymorph identity with human PK ceilings and endpoints. It forces challengers to address both solid-state and in vivo performance.
References (APA)
[No cited sources were provided in the prompt.]
More… ↓
⤷ Start Trial
|
